As previously reported, Wells Fargo analyst Derek Archila downgraded Arvinas to Equal Weight from Overweight with a price target of $49, down from $83. The analyst sees limited catalysts in 2023 that will improve sentiment on ARV-471.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Barclays views GSK acquisition interest as positive for oncology stocks
- Arvinas downgraded to Equal Weight from Overweight at Wells Fargo
- Arvinas appoints Everett Cunningham to board of directors
- Arvinas Announces Changes to its Board of Directors
- Arvinas price target lowered to $72 from $88 at Citi
